Corticosteroids for idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF), also called cryptogenic fibrosing alveolitis (CFA), is a lethal form of diffuse lung disorder of unknown origin; the mean survival being two to four years. Currently recommended and most prescribed therapy for IPF is based on the use of systemic corticosteroids, even if no formal demonstration of efficacy of this treatment of IPF is available. Furthermore, new insights from pathological studies have produced a new hypothesis, based upon the central role played by aberrant wound healing following repeated lung injury, weakening the rationale basis of the use of corticosteroids in IPF, previously considered simply a chronic inflammatory disease. OBJECTIVES: The objective of the review was to determine the efficacy of corticosteroids in the treatment of adults with IPF. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2002), MEDLINE (January 1966 to May 2002) and EMBASE (January 1985 to December 2002) and reference lists of articles. We searched reference lists of published articles to identify trials. SELECTION CRITERIA: Randomised controlled trials (RCT) and controlled clinical trials (CCT) using corticosteroids alone for the treatment of adults with IPF. DATA COLLECTION AND ANALYSIS: Abstracts of identified articles were retrieved and articles possibly fulfilling inclusion criteria were retrieved in full. Two reviewers would have independently assessed trial quality if there had been any included studies. MAIN RESULTS: Fifteen studies were selected as potentially eligible for meta-analysis. After further analysis of full text papers, no RCTs or CCTs were identified as suitable and therefore no data was available for inclusion in any meta-analysis. All studies were excluded due to inadequate methodologies. REVIEWER'S CONCLUSIONS: At present, there is no evidence for an effect of corticosteroid treatment in patients with Idiopathic pulmonary fibrosis(IPF)/usual interstitial pneumonia (UIP). Given developments in understanding of the pathogenesis of IPF, randomised controlled trials designed to test the efficacy of corticosteroids will probably never be designed. As other forms of pulmonary fibrosis such as non-specific interstitial pneumonia are reported to show a better response to corticosteroids, it is crucial to make an accurate diagnosis in each patient. Moreover, therapies with immunomodulatory rather than anti-inflammatory or immunosuppressive effects may be more promising for the effective treatment of IPF/UIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Systemic corticosteroids have been widely studied in the treatment of IPF with systematic reviews and meta-analyses failing to show any therapeutic benefit [23,52,53].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Gross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.-H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411703 · Cited by 586
Classification and Natural History of the Idiopathic Interstitial Pneumonias
Kim, D. S., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-005tk · Cited by 431
Raghu, G., Depaso, W. J., Cain, K., Hammar, S. P., Wetzel, C. E., Dreis, D. F., Hutchinson, J., Pardee, N. E., & Winterbauer, R. H. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.2.291 · Cited by 414
Idiopathic Pulmonary Fibrosis: Predicting Response to Therapy and Survival
GAY, S. E., KAZEROONI, E. A., TOEWS, G. B., LYNCH, J. P., GROSS, B. H., CASCADE, P. N., SPIZARNY, D. L., FLINT, A., ANTHONY SCHORK, M., WHYTE, R. I., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9703022 · Cited by 406
Johnson, M. A., Kwan, S., Snell, N. J., Nunn, A. J., Darbyshire, J. H., & Turner-Warwick, M. (1989) · Thorax · doi:10.1136/thx.44.4.280 · Cited by 289
DOUGLAS, W. W., RYU, J. H., & SCHROEDER, D. R. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9907002 · Cited by 259
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationGlucocorticoid resistance in inflammatory diseases
Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983
Interstitial lung disease guideline
Wells, A. U., Hirani, N., & on behalf of the BTS Interstitial Lung Disease Guideline Group, A. S. O. T. B. T. S. S. O. C. C. (2008) · Thorax · doi:10.1136/thx.2008.101691 · Cited by 866
Pulmonary fibrosis: pathogenesis, etiology and regulation
Wilson, M. S., & Wynn, T. A. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.85 · Cited by 822
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Histone acetylation and deacetylation: importance in inflammatory lung diseases
Barnes, P. J., Adcock, I. M., & Ito, K. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00117504 · Cited by 564
Molecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · Chest · doi:10.1378/chest.06-2568 · Cited by 538
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Meltzer, E. B., & Noble, P. W. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-8 · Cited by 407
Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model
Chaudhary, N. I., Schnapp, A., & Park, J. E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-717oc · Cited by 358
Strategies for treating idiopathic pulmonary fibrosis
du Bois, R. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2958 · Cited by 251
The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis
Murtha, L. A., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Knight, D. A., & Boyle, A. J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00777 · Cited by 229
“The role of inflammation in the progression of fibrosis in IPF has been challenged because anti-inflammatory and immunosuppressive agents are ineffective as therapies (Davies et al., 2003; Richeldi et al., 2003).”
BackgroundHow does comorbidity influence survival in idiopathic pulmonary fibrosis?
Hyldgaard, C., Hilberg, O., & Bendstrup, E. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.01.008 · Cited by 180
“There is no evidence that corticosteroid therapy modifies the natural history of the disease, and recommendations against its use are strong [2,9].”
BackgroundCurrent Perspectives on the Treatment of Idiopathic Pulmonary Fibrosis
Walter, N., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200602-016tk · Cited by 174
Non-steroid agents for idiopathic pulmonary fibrosis
Spagnolo, P., Del Giovane, C., Luppi, F., Cerri, S., Balduzzi, S., Walters, E. H., D'Amico, R., & Richeldi, L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003134.pub2 · Cited by 163
Self-citationOutcomes and Safety of Surgical Lung Biopsy for Interstitial Lung Disease
Lettieri, C. J., Veerappan, G. R., Helman, D. L., Mulligan, C. R., & Shorr, A. F. (2005) · Chest · doi:10.1378/chest.127.5.1600 · Cited by 159
Macrophage heterogeneity in respiratory diseases
Boorsma, C. E., Draijer, C., & Melgert, B. N. (2013) · Mediators of Inflammation · doi:10.1155/2013/769214 · Cited by 126
Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit
Mallick, S. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.06.003 · Cited by 142
“Corticosteroids and immunosuppressants have not shown any significant benefit.(27,28) As the disease progresses therapeutic intervention is mainly palliative.”
BackgroundA review of current and novel therapies for idiopathic pulmonary fibrosis.
Rafii, R., Juarez, M. M., Albertson, T. E., & Chan, A. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.12.07 · Cited by 175
Histone Deacetylation: An Important Mechanism in Inflammatory Lung Diseases
Adcock, I. M., Ito, K., & Barnes, P. J. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550500346683 · Cited by 149
Normativa sobre el diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.03.011 · Cited by 142
Japanese guideline for the treatment of idiopathic pulmonary fibrosis
Homma, S. A., Bando, M., Azuma, A., Sakamoto, S., Sugino, K., Ishii, Y., Izumi, S., Inase, N., Inoue, Y., Ebina, M., et al. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.003 · Cited by 135
Immune Mechanisms of Pulmonary Fibrosis with Bleomycin
Ishida, Y., Kuninaka, Y., Mukaida, N., & Kondo, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043149 · Cited by 136
Newton, R., Leigh, R., & Giembycz, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.003 · Cited by 132
“There is no evidence that glucocorticoid treatment impacts the natural course of those conditions characterised by pulmonary fibrosis (Richeldi et al., 2003).”
Rudd, R. M., Prescott, R. J., Chalmers, J. C., Johnston, I. D. A., & for the Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society (2007) · Thorax · doi:10.1136/thx.2005.045591 · Cited by 113
Smith, M. R., Gangireddy, S. R., Narala, V. R., Hogaboam, C. M., Standiford, T. J., Christensen, P. J., Kondapi, A. K., & Reddy, R. C. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00002.2009 · Cited by 121
Gharaee‐Kermani, M., Gyetko, M. R., Hu, B., & Phan, S. H. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9216-x · Cited by 112
Recent Advances in Idiopathic Pulmonary Fibrosis
Noth, I., & Martínez, F. J. (2007) · CHEST Journal · doi:10.1378/chest.06-1927 · Cited by 109
Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment
Khalil, N. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1030055 · Cited by 98
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Bouros, D. E., & Antoniou, K. M. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00145004 · Cited by 97
Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
Ghonim, M. A., Boyd, D. F., Flerlage, T., & Thomas, P. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170499 · Cited by 95
S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
Behr, J., Günther, A., Ammenwerth, W., Bittmann, I., Bonnet, R. B., Buhl, R., Eickelberg, O., Ewert, R., Gläser, S., Gottlieb, J., et al. (2013) · Pneumologie · doi:10.1055/s-0032-1326009 · Cited by 110
Chennakesavulu, S., Mishra, A. K., Sudheer, A., Sowmya, C., Reddy, C. S., & Bhargav, E. (2017) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.08.005 · Cited by 99
COVID-19 and corticosteroids: a narrative review
Batiha, G. E., Al-Gareeb, A. I., Saad, H. M., & Al-Kuraishy, H. M. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00987-z · Cited by 95
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study
Harari, S., Caminati, A., Albera, C., Vancheri, C., Poletti, V., Pesci, A., Luppi, F., Saltini, C., Agostini, C., Bargagli, E., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.04.010 · Cited by 78
Self-citationHuang, X., He, Y., Chen, Y., Wu, P., Gui, D., Cai, H., Chen, A., Chen, M., Dai, C., Yao, D., et al. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0294-1 · Cited by 85
Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis
Serrano‐Mollar, A., Gay-Jordi, G., Guillamat‐Prats, R., Closa, D., Hernández‐González, F., Marín, P., Burgos, F., Martorell, J., Sánchez, M., Arguis, P., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.03.021 · Cited by 80
Shieh, J., Tseng, H., Jung, F., Yang, S., & Lin, J. (2019) · Mediators of Inflammation · doi:10.1155/2019/7947596 · Cited by 75
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Cottin, V., Richeldi, L., Rosas, I. O., Otaola, M., Song, J. W., Tomassetti, S., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01668-1 · Cited by 79
Self-citationIdiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs
Hadjicharalambous, M. R., & Lindsay, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020524 · Cited by 75
“As is the case with most ILDs, inflammation was initially thought to be the major player in IPF until unresponsiveness to anti-inflammatory medications prompted the re-evaluation of this idiom [8,9].”
BackgroundClinical review: Idiopathic pulmonary fibrosis acute exacerbations - unravelling Ariadne's thread
Papiris, S. A., Manali, E. D., Kolilekas, L., Kagouridis, K., Triantafillidou, C., Tsangaris, I., & Roussos, C. (2010) · Critical Care · doi:10.1186/cc9241 · Cited by 71
“However, Cochrane reviews for the effi cacy of these therapies concluded that there is no evidence for any benefi t of both cortico steroids and immunosuppressants in IPF [60,61].”
BackgroundShochet, G. E., Brook, E., Israeli‐Shani, L., Edelstein, E., & Shitrit, D. (2017) · Respiratory Research · doi:10.1186/s12931-017-0606-x · Cited by 76
Addis-Lieser, E., Köhl, J., & Chiaramonte, M. G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1894 · Cited by 65
Martínez, F. J. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200511-123jh · Cited by 68
Review: Therapies for interstitial lung disease: past, present and future
Kim, R., & Meyer, K. C. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808096948 · Cited by 66
“Moreover, a thorough Cochrane Review underscored the lack of any randomized, controlled trials that would allow a definitive recommendation regarding the use of corticosteroid for IPF/UIP to be made [Richeldi et al. 2003].”
BackgroundEfficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis
Sun, T., Liu, J., & Zhao, D. W. (2016) · Medicine · doi:10.1097/md.0000000000003629 · Cited by 59
Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
Maher, T. M. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.002 · Cited by 70
Zisman, D. A., Keane, M. P., Belperio, J. A., Strieter, R. M., & Lynch, J. P. (2005) · Humana Press eBooks · doi:10.1385/1-59259-940-0:003 · Cited by 75
Checa, J., & Aran, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239317 · Cited by 61
Workshop on Idiopathic Pulmonary Fibrosis in Older Adults
Castriotta, R. J., Eldadah, B. A., Foster, W. M., Halter, J. B., Hazzard, W. R., Kiley, J. P., King, T. E., Horne, F. M., Nayfield, S., Reynolds, H. Y., et al. (2010) · CHEST Journal · doi:10.1378/chest.09-3006 · Cited by 60
Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis
Hilberg, O., Simonsen, U., du Bois, R. M., & Bendstrup, E. M. (2012) · The Clinical Respiratory Journal · doi:10.1111/j.1752-699x.2012.00302.x · Cited by 60
Venosa, A., Katzen, J. B., Tomer, Y., Kopp, M. C., Jamil, S., Russo, S. J., Mulugeta, S., & Beers, M. F. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900039 · Cited by 55
The Epithelial-Immune Crosstalk in Pulmonary Fibrosis
Planté-Bordeneuve, T., Pilette, C., & Froidure, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631235 · Cited by 67
“Although randomized controlled trials evaluating the role of steroids were missing (3, 4), observational data suggested a heterogeneous response in patients (5).”
BackgroundSaidi, A., Kasabova, M., Vanderlynden, L., Wartenberg, M., Kara-Ali, G. H., Marc, D., Lecaille, F., & Lalmanach, G. (2019) · Scientific Reports · doi:10.1038/s41598-018-36858-3 · Cited by 56
Swigris, J. J., Kuschner, W. G., Kelsey, J. L., & Gould, M. K. (2005) · CHEST Journal · doi:10.1378/chest.127.1.275 · Cited by 86
Li, M., Ping, G., Plathow, C., Trinh, T., Lipson, K. E., Hauser, K., Krempien, R. C., Debus, J., Abdollahi, A., & Huber, P. E. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-79 · Cited by 52
Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2016.12.011 · Cited by 58
Roach, K. M., Sutcliffe, A., Matthews, L., Elliott, G., Newby, C., Amrani, Y., & Bradding, P. (2018) · Scientific Reports · doi:10.1038/s41598-017-18555-9 · Cited by 50
Spontaneous Lung Fibrosis Resolution Reveals Novel Antifibrotic Regulators
Tan, Q., Link, P. A., Meridew, J. A., Pham, T. X., Caporarello, N., Ligresti, G., & Tschumperlin, D. J. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0396oc · Cited by 61
Fibrosis, chronic inflammation and new pathways for drug discovery
Sivakumar, P., & Das, A. (2008) · Inflammation Research · doi:10.1007/s00011-008-7166-y · Cited by 49
Varney, V., Parnell, H., Salisbury, D., Ratnatheepan, S., & Tayar, R. (2007) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2007.02.001 · Cited by 53
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis
Luppi, F., Cerri, S., Beghé, B., Fabbri, L. M., & Richeldi, L. (2004) · Respiratory Medicine · doi:10.1016/j.rmed.2004.07.019 · Cited by 49
Self-citationClinical review: Idiopathic pulmonary fibrosis—Past, present and future
Dempsey, O. J. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.08.017 · Cited by 62
Wilfong, E. M., Lentz, R. J., Guttentag, A. R., Tolle, J., Johnson, J. E., Kropski, J. A., Kendall, P. L., Blackwell, T. S., & Crofford, L. J. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40679 · Cited by 51
Adegunsoye, A., & Balachandran, J. S. (2015) · Mediators of Inflammation · doi:10.1155/2015/510105 · Cited by 46
Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.03.001 · Cited by 49
Accumulation of BDCA1+ Dendritic Cells in Interstitial Fibrotic Lung Diseases and Th2-High Asthma
Greer, A. M., Matthay, M. A., Kukreja, J., Bhakta, N. R., Nguyen, C. P., Wolters, P. J., Woodruff, P. G., Fahy, J. V., & Shin, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099084 · Cited by 47
McMillan, D. H., van der Velden, J. L. J., Lahue, K. G., Qian, X., Schneider, R. W., Iberg, M. S., Nolin, J. D., Abdalla, S. T., Casey, D. T., Tew, K. D., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85717 · Cited by 44
Zhang, H., Liu, X., Chen, S., Wu, J., Ye, X., Xu, L., Chen, H., Zhang, D., Tan, R. X., & Wang, Y. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.06.022 · Cited by 40
Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines
Чучалин, А. Г., Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Демура, Т. А., Ilkovich, M. M., Коган, Е. А., Samsonova, M. V., Speranskaya, A. A., Tyurin, I. E., et al. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-4-399-419 · Cited by 49
Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis
Kim, Y.-I., Shin, H., Chun, Y., Cho, C., Koh, J., Chung, D. H., & Park, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0530-0 · Cited by 47
Tülek, B., Kıyan, E., Toy, H., Kıyıcı, A., Narin, C., & Süerdem, M. (2011) · Clinical and investigative medicine · doi:10.25011/cim.v34i6.15894 · Cited by 42
Loveman, E., Copley, V. R., Colquitt, J. L., Scott, D. A., Clegg, A. J., Jones, J., O’Reilly, K. M., Singh, S., Bausewein, C., & Wells, A. U. (2015) · Health Technology Assessment · doi:10.3310/hta19200 · Cited by 41
Fiorucci, E., Lucantoni, G., Paone, G., Zotti, M., Li, B. E., Serpilli, M., Regimenti, P., Cammarella, I., Puglisi, G., & Schmid, G. (2008) · PubMed · Cited by 43
Update on diagnosis and treatment of idiopathic pulmonary fibrosis
Martínez, J. A. B., Baldi, B. G., da Costa, C. H., Jezler, S. F. D. O., Lima, M. S., & Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000152 · Cited by 43
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.11.035 · Cited by 45
New perspectives on management of idiopathic pulmonary fibrosis
Puglisi, S., Torrisi, S. E., Vindigni, V., Giuliano, R., Palmucci, S., Mulè, M., & Vancheri, C. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315624276 · Cited by 38
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.004 · Cited by 41
Evidence-based treatment strategies in idiopathic pulmonary fibrosis
Behr, J. (2013) · European Respiratory Review · doi:10.1183/09059180.00001013 · Cited by 40
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
Sköld, C. M., Bendstrup, E. M., Myllärniemi, M., Guðmundsson, G., Sjåheim, T., Hilberg, O., Altraja, A., Kaarteenaho, R. L., & Ferrara, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12571 · Cited by 38
Efficacy of antioxidant in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Kandhare, A. D., Mukherjee-Kandhare, A. A., Ghosh, P., & Bodhankar, S. L. (2016) · EXCLI journal · doi:10.17179/excli2016-619 · Cited by 39
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
Bailey, C. D., Wagland, R., Dabbour, R. S., Caress, A., Smith, J. A., & Molassiotis, A. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-63 · Cited by 34
Thiam, F., Phogat, S., Abokor, F. A., & Osei, E. T. (2023) · Respiratory Research · doi:10.1186/s12931-023-02608-x · Cited by 33
Stem cell-based therapy for fibrotic diseases: mechanisms and pathways
Taherian, M., Bayati, P., & Mojtabavi, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03782-5 · Cited by 39
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future
Staitieh, B. S., Renzoni, E. A., & Veeraraghavan, S. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.991751 · Cited by 32
Piotrowski, W. J., Bestry, I., Białas, A. J., Boros, P. W., Grzanka, P., Jassem, E., Jastrzębski, D., Klimczak, D., Langfort, R., Lewandowska, K. B., et al. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2020.0081 · Cited by 32
Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis
O’Dwyer, D. N., Armstrong, M. E., Kooblall, M., & Donnelly, S. C. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988706 · Cited by 29
Promising pharmacologic innovations in treating pulmonary fibrosis
Bhatt, N., Baran, C., ALLEN, J., MAGRO, C. M. J., & Marsh, C. B. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.003 · Cited by 29
Venosa, A., Cowman, S. J., Katzen, J. B., Tomer, Y., Armstrong, B. S., Mulugeta, S., & Beers, M. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665818 · Cited by 33
Pedraza-Serrano, F., López‐de‐Andrés, A., Jiménez‐García, R., Jiménez‐Trujillo, I., Hernández‐Barrera, V., Sánchez-Muñoz, G., Puente‐Maestu, L., & de Miguel‐Díez, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013156 · Cited by 27
Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders
Sofias, A. M., Lorenzi, F. D., Peña, Q., Shalmani, A. A., Vucur, M., Wang, J., Kiessling, F. M., Shi, Y., Consolino, L., Storm, G., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113831 · Cited by 28
“For decades, first-line anti-fibrotic interventions have been based on corticosteroids and immunosuppressants [205,206].”
BackgroundHerink, M. C., Irwin, A. N., & Zumach, G. M. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2167 · Cited by 26
Emerging drugs for idiopathic pulmonary fibrosis
Selman, M., Pardo, A., Richeldi, L., & Cerri, S. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.565049 · Cited by 29
Self-citationTargeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis
Lee, S., Lee, C.-M., Ma, B., Kamle, S., Elias, J. A., Zhou, Y., & Lee, C. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.826471 · Cited by 32
“Since the role of specific inflammatory cells in the pathogenesis of fibrosis is controversial (Gauldie, 2002; Strieter, 2002), antiinflammatory agents represented by corticosteroids did not show a significant effect in the treatment of IPF (Richeldi et al., 2003).”
BackgroundRosa, A. C., Pini, A., Lucarini, L., Lanzi, C., Veglia, E., Thurmond, R. L., Stark, H., & Masini, E. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.215152 · Cited by 25
Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.06.003 · Cited by 48
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis
Richeldi, L. (2012) · European Respiratory Review · doi:10.1183/09059180.00000912 · Cited by 26
Self-citation
Metadata
- Authors
- Richeldi, L., Davies, H. R. H. R., Spagnolo, P., & Luppi, F.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Repatriation General Hospital (AU)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2003-07-21
- Issue
- 3
- Pages
- CD002880-CD002880
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC8457302
- OpenAlex
- W1710057076
- Cited by
- 219
- References
- 23
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 11 · 2018: 12 · 2017: 14 · 2016: 11 · 2015: 11 · 2014: 10 · 2013: 15 · 2012: 10
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, usual interstitial pneumonia, corticosteroids, systemic corticosteroid therapy, treatment efficacy, aberrant wound healing, lung injury, immunomodulatory therapy, nonspecific interstitial pneumonia
- MeSH terms
- Adrenal Cortex Hormones, Adult, Humans, Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.